ESMO Targeted Anticancer Therapies Asia Congress 2025
Target-led treatments for lung cancer – are they moving to the next level?
Antibody–drug conjugates may represent a step up from existing therapeutic options, but further optimisation and biomarker analyses are required.
Machine learning approach identifies the enzyme MMP2 as a key target for drug repurposing in advanced cervical cancer
Additional treatment targets and potentially repurposable agents were identified based on chemoradiotherapy response, which could now be explored for further validation.
Technology integration and access to eligible patients underpin the growth of early-phase trials in Asia Pacific
Global cooperation is needed to improve trial design and expedite new treatments specifically in low- and middle-income countries
Patient-reported outcomes in dose-finding show value in oncology trial inclusion, but shared standards are needed
Findings from studies show that patient-centred evidence can inform decisions in early-phase cancer research